Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

PET in prostate and bladder tumors.

Sze Ting Lee1, Nathan Lawrentschuk, Andrew M Scott

  • 1Centre for PET, Austin Hospital, Melbourne, Australia.

Seminars in Nuclear Medicine
|June 12, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator.

Clinical and translational radiation oncology·2026
Same author

A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Identifying factors associated with sleep disturbance among adults seeking outpatient psychiatric services for anxiety and related disorders.

Bulletin of the Menninger Clinic·2026
Same author

Cancer workforce-a global crisis: a Lancet Oncology Commission.

The Lancet. Oncology·2026
Same author

Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers.

The Lancet. Oncology·2026
Same author

Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers.

The Lancet. Oncology·2026
Same journal

Cost-effectiveness of imaging modalities in coronary heart disease: A comprehensive review.

Seminars in nuclear medicine·2026
Same journal

Letter from the Editors.

Seminars in nuclear medicine·2026
Same journal

Expanding Horizons: The Role of Kaleidoscope and Relevant Images in Seminars in Nuclear Medicine.

Seminars in nuclear medicine·2026
Same journal

The diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma - A systematic review and meta-analysis.

Seminars in nuclear medicine·2026
Same journal

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies.

Seminars in nuclear medicine·2026
Same journal

<sup>18</sup>F-FDG -PET/CT in cardiac sarcoidosis: Diagnosis, therapy monitoring, and future directions.

Seminars in nuclear medicine·2026
See all related articles

(18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) shows limited use in prostate and bladder cancers due to low uptake and excretion. However, FDG-PET can aid in staging advanced prostate cancer and identifying bladder cancer with diuresis.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • (18)F-fluorodeoxyglucose (FDG) is a common radiotracer for PET imaging in prostate and bladder cancers.
  • Its utility is limited by low metabolic rates in primary prostate cancer and urinary excretion that can obscure tumors.
  • Physiological FDG excretion can mimic or mask tumor uptake in the urinary tract.

Purpose of the Study:

  • To evaluate the role of FDG-PET in the diagnosis, staging, and restaging of prostate and bladder cancers.
  • To explore the effectiveness of FDG-PET in specific patient populations and disease stages.
  • To assess the potential of new PET tracers for improved cancer characterization.

Main Methods:

  • Review of current literature and clinical applications of FDG-PET in urological malignancies.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Experiment Videos

Last Updated: May 21, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

  • Discussion of diagnostic challenges and strategies, including diuresis protocols.
  • Consideration of emerging PET tracers for enhanced biological characterization.

    • Main Results:

    • FDG-PET has a role in selected cases for staging and restaging advanced prostate cancer, especially with rising PSA levels.
    • Diuresis strategies improve the detection of primary bladder cancer and staging of extravesical disease.
    • FDG-PET can be beneficial for ureteric and urethral cancers.

    Conclusions:

    • FDG-PET is valuable in specific scenarios for prostate and bladder cancer evaluation, particularly with optimized imaging techniques.
    • New PET tracers offer promising advancements in staging and biological characterization, aiding therapeutic decisions.
    • Further research into novel PET agents is crucial for improving patient management in urological cancers.